SCHEMBL23958160

SCHEMBL23958160

COc1cccnc1Nc1nc2ccc(F)cc2c(=O)n1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 4/20 0.45
PI4KA P42356 3/20 0.45
POLB P06746 3/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
HTR7 P34969 3/20 0.44
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
HTR2C P28335 1/20 0.44
PIK3CD O00329 1/20 0.44
PIK3C3 Q8NEB9 1/20 0.44
TP53 P04637 1/20 0.42
TDO2 P48775 1/20 0.42
IDO2 Q6ZQW0 1/20 0.42
MAT2A P31153 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24110922 0.87 TDO2 (0.46) PIK3CGPOLBALDH1A1HTR7HTR1A
SCHEMBL24111043 0.87 TDO2 (0.45) PIK3CGPI4KAPOLBHTR7PIK3CD
SCHEMBL23958260 0.83 PI4KA (0.46) PIK3CGPI4KAPOLBMAPTKDM4E
SCHEMBL24110947 0.82 TDO2 (0.45) PIK3CGPI4KAPOLBPIK3CDPIK3C3
SCHEMBL23958170 0.82 POLB (0.42) PIK3CGPI4KAPOLBMAPTKDM4E
SCHEMBL23958159 0.82 HTR7 (0.45) PIK3CGPI4KAPOLBALDH1A1HTR7
SCHEMBL23958125 0.81 MAT2A (0.47) PIK3CGPI4KAPOLBHTR7PIK3CD
SCHEMBL23045334 0.80 TDO2 (0.50) PIK3CGPOLBMAPTRAB9AHTR7
SCHEMBL29623155 0.80 TDO2 (0.50) PIK3CGPOLBMAPTRAB9AHTR7
SCHEMBL24111048 0.79 TDO2 (0.46) PIK3CGPI4KAPOLBHTR7PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 PIK3CG 3250/4885PI4KA 1298/4885POLB 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.